Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATITUDE-PsA-3001 phase 3 study of zasocitinib in active psoriatic arthritis
MOH_2025-02-10_013902Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zasocitinib in psoriatic arthritis (PsA) (4 arms), sponsored by Takeda. Started Dec 2024; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on MOH_2025-02-10_013902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-10_013902.